| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Cameron Gray last filed a Form 4 in June 2022, as Director at CUE. Cameron Gray's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 687,049 shares of CUE. Net of sales, the CUE filings show accumulation of 10,000 shares.
Cameron Gray has 8 Form 4 filings on record from December 2017 to June 2022, all as Director at Cue Biopharma (CUE), 2017–2022.
The 9 reported transactions were 4 option or other derivative awards, 2 open-market purchases, 1 option exercise and 1 tax withholding, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $152K and no sales.
The only open-market purchase was 10,000 shares of CUE at an average $15.15 on September 30, 2020, about $152K.
Shares as reported in the last Form 4 for each company; the most recent is from June 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2020 | CUE Cue Biopharma, Inc. | Director | Buy | 10,000 | $15.15 | $151,500.00 | +1.5% |